3.20Open3.20Pre Close0 Volume2 Open Interest2.00Strike Price0.00Turnover594.02%IV25.91%PremiumNov 29, 2024Expiry Date2.13Intrinsic Value100Multiplier4DDays to Expiry1.07Extrinsic Value100Contract SizeAmericanOptions Type0.9336Delta0.0517Gamma1.86Leverage Ratio-0.0412Theta0.0002Rho1.73Eff Leverage0.0005Vega
Inovio Pharmaceuticals Stock Discussion
Inovio Announces New Data at Scientific Conferences for Lead Candidate, Ino-3107, as a Potential Treatment for Rrp
On Friday, the fear of human-to-human spread grew ever so slightly: The CDC confirmed that four health-care workers in Missouri had fallen sick after caring for a patient who was infected with bird flu.
https://www.msn.com/en-us/health/other/bird-flu-pandemic-fears-skyrocket-as-us-identifies-first-cases-of-possible-human-to-human-transmission/ar-AA1rwhf5?ocid=BingNewsSerp
Inovio Receives Advanced Therapy Medicinal Product Certificate From European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate Ino-3107
• BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgicaltreatment for recurrent respiratory papillomatosis (RRP)
• Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
• Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM ...
No comment yet